Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Coherus Oncology, Inc. (CHRS : NSDQ)

• Company Description    Coherus is a fully integrated commercial-stage innovative oncology company. Coherus, formerly known as Coherus BioSciences Inc., is based in REDWOOD CITY, Calif. Number of Employees: 147

• Price / Volume Information    Yesterday's Closing Price: $1.63 Daily Weekly Monthly 20 Day Moving Average: 1,565,154 shares Shares Outstanding: 149.89 (millions) Market Capitalization: $244.32 (millions) Beta: 1.04 52 Week High: $2.62 52 Week Low: $0.71 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -3.55% 4.63% 12 Week 14.79% 23.38% Year To Date 14.79% 23.55%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 333 TWIN DOLPHIN DRIVE SUITE 600 - REDWOOD CITY,CA 94065 USA ph: 650-649-3530 fax: - ir@coherus.com http://www.coherus.com

• General Corporate Information    Officers Dennis M. Lanfear - Chief Executive Officer; Chairman and President Bryan McMichael - Chief Financial Officer Georgia Erbez - Director Lee N. Newcomer - Director Charles W. Newton - Director Peer Information Coherus Oncology, Inc. (CORR.) Coherus Oncology, Inc. (RSPI) Coherus Oncology, Inc. (CGXP) Coherus Oncology, Inc. (BGEN) Coherus Oncology, Inc. (GTBP) Coherus Oncology, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 19249H103 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/11/26 Share - Related Items Shares Outstanding: 149.89 Most Recent Split Date: (:1) Beta: 1.04 Market Capitalization: $244.32 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.29 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.93 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.23 Price/Cash Flow: - Price / Sales: 5.79 EPS Growth vs. Year Ago Period: 11.36% vs. Previous Quarter: -2.63% Sales Growth vs. Year Ago Period: -76.46% vs. Previous Quarter: 10.17% ROE 12/31/25 - -860.29 09/30/25 - - 06/30/25 - - ROA 12/31/25 - -46.20 09/30/25 - -42.23 06/30/25 - -34.85 Current Ratio 12/31/25 - 1.47 09/30/25 - 1.24 06/30/25 - 1.44 Quick Ratio 12/31/25 - 1.45 09/30/25 - 1.23 06/30/25 - 1.43 Operating Margin 12/31/25 - -434.23 09/30/25 - -224.34 06/30/25 - -107.66 Net Margin 12/31/25 - 398.42 09/30/25 - 185.44 06/30/25 - 125.90 Pre-Tax Margin 12/31/25 - -434.23 09/30/25 - -217.41 06/30/25 - -129.41 Book Value 12/31/25 - 0.50 09/30/25 - 0.76 06/30/25 - 1.03 Inventory Turnover 12/31/25 - 4.17 09/30/25 - 3.51 06/30/25 - 0.77 Debt-to-Equity 12/31/25 - 0.61 09/30/25 - 0.42 06/30/25 - 0.31 Debt-to-Capital 12/31/25 - 37.78 09/30/25 - 29.63 06/30/25 - 23.53

Powered by Zacks Investment Research ©